475 related articles for article (PubMed ID: 8400928)
1. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
[TBL] [Abstract][Full Text] [Related]
2. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees AJ
BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
[TBL] [Abstract][Full Text] [Related]
3. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
[TBL] [Abstract][Full Text] [Related]
4. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Lees AJ; Katzenschlager R; Head J; Ben-Shlomo Y
Neurology; 2001 Nov; 57(9):1687-94. PubMed ID: 11706112
[TBL] [Abstract][Full Text] [Related]
5. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
6. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
[TBL] [Abstract][Full Text] [Related]
7. Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
Przuntek H; Welzel D; Schwarzmann D; Letzel H; Kraus PH
Eur Neurol; 1992; 32 Suppl 1():36-45. PubMed ID: 1425819
[TBL] [Abstract][Full Text] [Related]
8. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
9. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
[TBL] [Abstract][Full Text] [Related]
10. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
11. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
Montastruc JL; Rascol O; Senard JM; Rascol A
J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
[TBL] [Abstract][Full Text] [Related]
12. Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
Bouchard S
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):460-5. PubMed ID: 3676921
[TBL] [Abstract][Full Text] [Related]
13. Strategies in the treatment of early Parkinson's disease.
Rinne UK
Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
[TBL] [Abstract][Full Text] [Related]
14. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.
Rinne UK
Neurology; 1987 May; 37(5):826-8. PubMed ID: 3574685
[TBL] [Abstract][Full Text] [Related]
15. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
16. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
Elizan TS; Moros DA; Yahr MD
Arch Neurol; 1991 Jan; 48(1):31-4. PubMed ID: 1898848
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
18. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.
Ogawa N; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Yanagisawa N
Eur Neurol; 1997; 38 Suppl 2():37-49. PubMed ID: 9387802
[TBL] [Abstract][Full Text] [Related]
19. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen EH; Myllylä V
Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
[TBL] [Abstract][Full Text] [Related]
20. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
